Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.57 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104710 | 0.86 | TRPV4 (0.52) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL30892077 | 0.83 | CYP11B1 (0.45) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL2824439 | 0.83 | CYP11B1 (0.45) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL20487060 | 0.82 | TRPV4 (0.48) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL20656656 | 0.82 | TRPV4 (0.48) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL16649615 | 0.82 | TRPV4 (0.48) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL30408582 | 0.82 | CYP11B1 (0.60) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL22495734 | 0.82 | TRPV4 (0.48) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL28802774 | 0.82 | TRPV4 (0.48) | CYP11B2CYP11B1TRPV4S1PR3 | |
| SCHEMBL16956909 | 0.82 | TRPV4 (0.48) | CYP11B2CYP11B1TRPV4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-118475560-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023185811-A1 | NOVEL HETEROCYCLIC COMPOUND | 首药控股(北京)股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| CN-104016940-A | GW501516 synthetic method | BAIYIN BOTONG BIOCHEMISTRY CO LTD | 2014-09-03 | — | — | CN | disclosed |
| US-20100022596-A1 | EPOTHILONE ANALOGUES | ALTMANN KARL-HEINZ | 2010-01-28 | — | — | US | disclosed |
| EP-2094713-A1 | EPOTHILONE ANALOGUES MODIFIED AT POSITIONS C12-C13 AS ANTICANCER DRUGS | Novartis Ag (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008071404-A1 | EPOTHILONE ANALOGUES MODIFIED AT POSITIONS C12-C13 AS ANTICANCER DRUGS | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | CYP2C19, CYP2C18, XDH | CYP11B2 35/4885CYP11B1 42/4885TRPV4 2428/4885 |
| US-20100022596-A1 | EPOTHILONE ANALOGUES | EPOR, CYP11B2, DHPS | CYP11B2 2/4885CYP11B1 5/4885TRPV4 4800/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | CYP11B2 9/4885CYP11B1 48/4885TRPV4 2728/4885 |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | CYP2C19, CYP2C18, XDH | CYP11B2 35/4885CYP11B1 42/4885TRPV4 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.